Effect of antihypertensive drugs on specific markers of inflammation and disorders of carbohydrate metabolism in metabolic syndrome
The potential of certain drugs to affect specific markers of progression of hypertension should be taken into account in the rational pharmacotherapy of arterial hypertension (AH) in patients with metabolic syndrome (MS). Pharmacodynamic effects of the beta-blocker (BB) nebivolol, the average daily...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2014-12-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/695 |
| _version_ | 1797842047374196736 |
|---|---|
| author | TE Morozova TB Andruschishina ER Kuzmina |
| author_facet | TE Morozova TB Andruschishina ER Kuzmina |
| author_sort | TE Morozova |
| collection | DOAJ |
| description | The potential of certain drugs to affect specific markers of progression of hypertension should be taken into account in the rational pharmacotherapy of arterial hypertension (AH) in patients with metabolic syndrome (MS). Pharmacodynamic effects of the beta-blocker (BB) nebivolol, the average daily dose 5,3 ± 2,5 mg, were studied in 29 patients with stage I - II hypertension with signs of MS (men - 15, women - 14; mean age 52, 4 ± 10,32 years). Nebivolol, along with a high antihypertensive efficacy (achievement of target blood pressure in 76% of patients) and good safety profile, provides a complex effect on specific markers of inflammation and disorders of carbohydrate metabolism. The study showed a decrease in the high-sensitivity C-reactive protein (hs-CRP) from 3.15 (2.0; 4.18) mg/l to 2.3 (1.18; 4.03) mg/l (p = 0.001), intercellular adhesion molecules (iCAM-1) from 330,23 (295.7; 387.3) ng/ml to 310.07 (252.72; 370.4) ng/ml (p = 0.044) with no adverse effect on insulin resistance, as well as a reduction in the adipokine activity and overall cardiovascular risk. |
| first_indexed | 2024-04-09T16:41:33Z |
| format | Article |
| id | doaj.art-846cb7c7f71e4bfe83ae30886d7883ec |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:41:33Z |
| publishDate | 2014-12-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-846cb7c7f71e4bfe83ae30886d7883ec2023-04-23T06:56:39ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902014-12-0101210010510.21518/2079-701X-2014-12-100-105695Effect of antihypertensive drugs on specific markers of inflammation and disorders of carbohydrate metabolism in metabolic syndromeTE Morozova0TB Andruschishina1ER Kuzmina2First Moscow State Medical University named after I.M.SechenovFirst Moscow State Medical University named after I.M.SechenovFirst Moscow State Medical University named after I.M.SechenovThe potential of certain drugs to affect specific markers of progression of hypertension should be taken into account in the rational pharmacotherapy of arterial hypertension (AH) in patients with metabolic syndrome (MS). Pharmacodynamic effects of the beta-blocker (BB) nebivolol, the average daily dose 5,3 ± 2,5 mg, were studied in 29 patients with stage I - II hypertension with signs of MS (men - 15, women - 14; mean age 52, 4 ± 10,32 years). Nebivolol, along with a high antihypertensive efficacy (achievement of target blood pressure in 76% of patients) and good safety profile, provides a complex effect on specific markers of inflammation and disorders of carbohydrate metabolism. The study showed a decrease in the high-sensitivity C-reactive protein (hs-CRP) from 3.15 (2.0; 4.18) mg/l to 2.3 (1.18; 4.03) mg/l (p = 0.001), intercellular adhesion molecules (iCAM-1) from 330,23 (295.7; 387.3) ng/ml to 310.07 (252.72; 370.4) ng/ml (p = 0.044) with no adverse effect on insulin resistance, as well as a reduction in the adipokine activity and overall cardiovascular risk.https://www.med-sovet.pro/jour/article/view/695артериальная гипертензияагметаболический синдромфармакотерапия агантигипертензивные препаратымаркеры воспаленияинсулинорезистентностьсердечно-сосудистый рискбета-адреноблокаторынебивололнебилетarterial hypertensionahmetabolic syndromeah therapyantihypertensive drugsinflammatory markersinsulin resistancecardiovascular riskbeta-blockersnebivololnebilet |
| spellingShingle | TE Morozova TB Andruschishina ER Kuzmina Effect of antihypertensive drugs on specific markers of inflammation and disorders of carbohydrate metabolism in metabolic syndrome Медицинский совет артериальная гипертензия аг метаболический синдром фармакотерапия аг антигипертензивные препараты маркеры воспаления инсулинорезистентность сердечно-сосудистый риск бета-адреноблокаторы небиволол небилет arterial hypertension ah metabolic syndrome ah therapy antihypertensive drugs inflammatory markers insulin resistance cardiovascular risk beta-blockers nebivolol nebilet |
| title | Effect of antihypertensive drugs on specific markers of inflammation and disorders of carbohydrate metabolism in metabolic syndrome |
| title_full | Effect of antihypertensive drugs on specific markers of inflammation and disorders of carbohydrate metabolism in metabolic syndrome |
| title_fullStr | Effect of antihypertensive drugs on specific markers of inflammation and disorders of carbohydrate metabolism in metabolic syndrome |
| title_full_unstemmed | Effect of antihypertensive drugs on specific markers of inflammation and disorders of carbohydrate metabolism in metabolic syndrome |
| title_short | Effect of antihypertensive drugs on specific markers of inflammation and disorders of carbohydrate metabolism in metabolic syndrome |
| title_sort | effect of antihypertensive drugs on specific markers of inflammation and disorders of carbohydrate metabolism in metabolic syndrome |
| topic | артериальная гипертензия аг метаболический синдром фармакотерапия аг антигипертензивные препараты маркеры воспаления инсулинорезистентность сердечно-сосудистый риск бета-адреноблокаторы небиволол небилет arterial hypertension ah metabolic syndrome ah therapy antihypertensive drugs inflammatory markers insulin resistance cardiovascular risk beta-blockers nebivolol nebilet |
| url | https://www.med-sovet.pro/jour/article/view/695 |
| work_keys_str_mv | AT temorozova effectofantihypertensivedrugsonspecificmarkersofinflammationanddisordersofcarbohydratemetabolisminmetabolicsyndrome AT tbandruschishina effectofantihypertensivedrugsonspecificmarkersofinflammationanddisordersofcarbohydratemetabolisminmetabolicsyndrome AT erkuzmina effectofantihypertensivedrugsonspecificmarkersofinflammationanddisordersofcarbohydratemetabolisminmetabolicsyndrome |